A new CRISPR startup is betting regulators will ease up on gene-editing

A new CRISPR startup called Aurora Therapeutics is aiming to streamline the approval process for gene-editing drugs by developing a more flexible approach that allows for minor adjustments without the need for costly new trials. The startup, backed by $16 million from Menlo Ventures and advised by CRISPR co-inventor Jennifer Doudna, is targeting the rare inherited disease phenylketonuria (PKU) as its first focus. Aurora's strategy involves creating a single gene editor that can be personalized to correct multiple common mutations associated with PKU, potentially revolutionizing gene-editing treatments. The company's approach aligns with the FDA's recent endorsement of regulatory changes to accommodate personalized therapies that cannot be easily tested conventionally.